CD36 and neoplasm: There is evidence to suggest that SARIFA reflects the morphological manifestation of an aggressive tumor biology associated with alterations in lipid metabolism, such as the upregulation of FABP4 (fatty-acid binding protein 4) and CD36 (fatty-acid translocase, FAT) [7–9], which may not be limited to specific tumor types.